In recent years, nucleic acid therapeutics have advanced rapidly, gaining prominence as the “third modality” of drug discovery following small molecules and antibody therapeutics, driven by growing regulatory approvals and expanded clinical development.
The book “Experimental Medicine Supplement: Understanding and Leveraging the Latest Nucleic Acid Therapeutics” (published in June 2026) provides a comprehensive overview of these latest developments, covering the entire spectrum from fundamental technologies to clinical applications and social implementation.
In this publication, Hideaki Sato, President & CEO of Luxna Biotech Co., Ltd., contributed a chapter titled “Expansion of Antisense Therapeutic Applications Enabled by Bridged Nucleic Acids” in Chapter 2, “Chemical Synthesis and Chemical Modifications,” presenting advanced insights into nucleic acid therapeutics.
Nucleic acid therapeutics enable direct intervention in target molecules and genes that have traditionally been difficult to address through sequence-specific molecular recognition.
Their application is expanding beyond rare diseases to include common diseases, while also enabling personalized approaches such as N-of-1 medicine tailored to individual patients.
The current competitive landscape is shifting toward key areas such as delivery technologies (DDS), AI-driven design, manufacturing scalability, and safety and regulatory considerations. Through these advances, nucleic acid therapeutics are evolving from a research-focused technology into a scalable medical modality.
Luxna Biotech Co., Ltd. views these developments as a structural transformation in drug discovery and is committed to creating value through design-driven approaches and addressing unmet medical needs.
We are committed to advancing next-generation therapeutics by addressing these evolving trends.
________________________________________
Reference
Experimental Medicine Supplement: Understanding and Leveraging the Latest Nucleic Acid Therapeutics